196 related articles for article (PubMed ID: 19665484)
21. Molecular dynamics study of HIV-1 RT-DNA-nevirapine complexes explains NNRTI inhibition and resistance by connection mutations.
Vijayan RS; Arnold E; Das K
Proteins; 2014 May; 82(5):815-29. PubMed ID: 24174331
[TBL] [Abstract][Full Text] [Related]
22. Chimeric human immunodeficiency virus type 1 and feline immunodeficiency virus reverse transcriptases: role of the subunits in resistance/sensitivity to non-nucleoside reverse transcriptase inhibitors.
Auwerx J; North TW; Preston BD; Klarmann GJ; De Clercq E; Balzarini J
Mol Pharmacol; 2002 Feb; 61(2):400-6. PubMed ID: 11809865
[TBL] [Abstract][Full Text] [Related]
23. Conformational changes in HIV-1 reverse transcriptase induced by nonnucleoside reverse transcriptase inhibitor binding.
Sluis-Cremer N; Temiz NA; Bahar I
Curr HIV Res; 2004 Oct; 2(4):323-32. PubMed ID: 15544453
[TBL] [Abstract][Full Text] [Related]
24. p66/p51 and p51/p51 recombinant forms of reverse transcriptase from human immunodeficiency virus type 1--interactions with primer tRNA(Lys3), initiation of cDNA synthesis, and effect of inhibitors.
Dufour E; El Dirani-Diab R; Boulmé F; Fournier M; Nevinsky G; Tarrago-Litvak L; Litvak S; Andreola ML
Eur J Biochem; 1998 Jan; 251(1-2):487-95. PubMed ID: 9492322
[TBL] [Abstract][Full Text] [Related]
25. Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. Implications for mechanisms of drug inhibition and resistance.
Tantillo C; Ding J; Jacobo-Molina A; Nanni RG; Boyer PL; Hughes SH; Pauwels R; Andries K; Janssen PA; Arnold E
J Mol Biol; 1994 Oct; 243(3):369-87. PubMed ID: 7525966
[TBL] [Abstract][Full Text] [Related]
26. Structural basis for the resilience of efavirenz (DMP-266) to drug resistance mutations in HIV-1 reverse transcriptase.
Ren J; Milton J; Weaver KL; Short SA; Stuart DI; Stammers DK
Structure; 2000 Oct; 8(10):1089-94. PubMed ID: 11080630
[TBL] [Abstract][Full Text] [Related]
27. The lysine 65 residue in HIV-1 reverse transcriptase function and in nucleoside analog drug resistance.
Garforth SJ; Lwatula C; Prasad VR
Viruses; 2014 Oct; 6(10):4080-94. PubMed ID: 25341667
[TBL] [Abstract][Full Text] [Related]
28. Divergent evolution in reverse transcriptase (RT) of HIV-1 group O and M lineages: impact on structure, fitness, and sensitivity to nonnucleoside RT inhibitors.
Tebit DM; Lobritz M; Lalonde M; Immonen T; Singh K; Sarafianos S; Herchenröder O; Kräusslich HG; Arts EJ
J Virol; 2010 Oct; 84(19):9817-30. PubMed ID: 20631150
[TBL] [Abstract][Full Text] [Related]
29. Elucidating the inhibition mechanism of HIV-1 non-nucleoside reverse transcriptase inhibitors through multicopy molecular dynamics simulations.
Ivetac A; McCammon JA
J Mol Biol; 2009 May; 388(3):644-58. PubMed ID: 19324058
[TBL] [Abstract][Full Text] [Related]
30. Characterization of novel non-nucleoside reverse transcriptase (RT) inhibitor resistance mutations at residues 132 and 135 in the 51 kDa subunit of HIV-1 RT.
Nissley DV; Radzio J; Ambrose Z; Sheen CW; Hamamouch N; Moore KL; Tachedjian G; Sluis-Cremer N
Biochem J; 2007 May; 404(1):151-7. PubMed ID: 17286555
[TBL] [Abstract][Full Text] [Related]
31. Docking of non-nucleoside inhibitors: neotripterifordin and its derivatives to HIV-1 reverse transcriptase.
Zhou Z; Madrid M; Madura JD
Proteins; 2002 Dec; 49(4):529-42. PubMed ID: 12402361
[TBL] [Abstract][Full Text] [Related]
32. High-resolution view of HIV-1 reverse transcriptase initiation complexes and inhibition by NNRTI drugs.
Ha B; Larsen KP; Zhang J; Fu Z; Montabana E; Jackson LN; Chen DH; Puglisi EV
Nat Commun; 2021 May; 12(1):2500. PubMed ID: 33947853
[TBL] [Abstract][Full Text] [Related]
33. Effect of a bound non-nucleoside RT inhibitor on the dynamics of wild-type and mutant HIV-1 reverse transcriptase.
Zhou Z; Madrid M; Evanseck JD; Madura JD
J Am Chem Soc; 2005 Dec; 127(49):17253-60. PubMed ID: 16332074
[TBL] [Abstract][Full Text] [Related]
34. Efavirenz binding site in HIV-1 reverse transcriptase monomers.
Braz VA; Barkley MD; Jockusch RA; Wintrode PL
Biochemistry; 2010 Dec; 49(49):10565-73. PubMed ID: 21090588
[TBL] [Abstract][Full Text] [Related]
35. N348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance.
Yap SH; Sheen CW; Fahey J; Zanin M; Tyssen D; Lima VD; Wynhoven B; Kuiper M; Sluis-Cremer N; Harrigan PR; Tachedjian G
PLoS Med; 2007 Dec; 4(12):e335. PubMed ID: 18052601
[TBL] [Abstract][Full Text] [Related]
36. Compensatory role of double mutation N348I/M184V on nevirapine binding landscape: insight from molecular dynamics simulation.
Karubiu W; Bhakat S; Soliman ME
Protein J; 2014 Oct; 33(5):432-46. PubMed ID: 25107349
[TBL] [Abstract][Full Text] [Related]
37. Probing nonnucleoside inhibitor-induced active-site distortion in HIV-1 reverse transcriptase by transient kinetic analyses.
Xia Q; Radzio J; Anderson KS; Sluis-Cremer N
Protein Sci; 2007 Aug; 16(8):1728-37. PubMed ID: 17656585
[TBL] [Abstract][Full Text] [Related]
38. Structure of unliganded HIV-1 reverse transcriptase at 2.7 A resolution: implications of conformational changes for polymerization and inhibition mechanisms.
Hsiou Y; Ding J; Das K; Clark AD; Hughes SH; Arnold E
Structure; 1996 Jul; 4(7):853-60. PubMed ID: 8805568
[TBL] [Abstract][Full Text] [Related]
39. The amino acid Asn136 in HIV-1 reverse transcriptase (RT) maintains efficient association of both RT subunits and enables the rational design of novel RT inhibitors.
Balzarini J; Auwerx J; Rodríguez-Barrios F; Chedad A; Farkas V; Ceccherini-Silberstein F; García-Aparicio C; Velázquez S; De Clercq E; Perno CF; Camarasa MJ; Gago F
Mol Pharmacol; 2005 Jul; 68(1):49-60. PubMed ID: 15833734
[TBL] [Abstract][Full Text] [Related]
40. Structural basis for drug resistance mechanisms for non-nucleoside inhibitors of HIV reverse transcriptase.
Ren J; Stammers DK
Virus Res; 2008 Jun; 134(1-2):157-70. PubMed ID: 18313784
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
